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Background: The majority (90%) of anal cancers are human papillomavirus (HPV)-driven, identified using immunochemistry for
p16. Compared with HPV patients, those with HPVþ disease generally show improved survival, although relapse rates around
25% indicate a need for further stratification of this group.
Methods: Using two cohorts of anal cancer, previously characterised for p16, we assessed the prognostic value of tumour-
infiltrating lymphocytes (TILs).
Results: Tumour-infiltrating lymphocyte scores were used to stratify p16þ cases, where tumours with absent/low levels of TIL had
a relapse-free rate of 63%, as opposed to 92% with high levels of TIL (log rank P¼ 0.006).
Conclusions: Assessment of TIL adds to p16 status in the prognosis of anal cancer following chemo-radiotherapy and provides
evidence of the clinical importance of the immune response.
Squamous cell carcinomas of the anus and anal canal are relatively
rare tumours, though increasing in incidence for reasons unknown.
In keeping with other squamous cell cancers of the ano-genital
region and an increasing proportion of oropharyngeal cancer, they
are associated with high-risk human papillomavirus (HPV)
subtypes (Baracevic-Jones et al, 2015). Immunohistochemistry
for p16INK4A (p16) has been used as a surrogate for HPV
involvement and to identify a group of patients (p16 negative) with
very poor outcomes following chemo-radiotherapy (CRT) (Gilbert
et al, 2013; Koerber et al, 2014; Rodel et al, 2014; Serup-Hansen
et al, 2014). Relapse-free rates (RFRs) in p16þ cases were 64–84%
across the four studies as opposed to 35–52% in p16 cases. High
p16 expression correlated with female sex and, in some studies,
marginally lower stage at presentation. p16 retained independent
prognostic ability in all reported studies, but requires prospective
validation in a clinical trial prior to entering routine use (or being
used to stratify treatments in future trials). However, rates of
p16 positivity ranged from 65% (Rodel et al, 2014) to 93%
(Serup-Hansen et al, 2014); hence the majority of relapses still
occur in p16þ patients.
One biological explanation for the improved outcomes follow-
ing CRT in p16þ cases rests on intact apoptotic mechanisms, with
low rates of p53 mutations described in p16þ head and neck
(Westra et al, 2008) and anal cancer (Meulendijks et al, 2015).
Human papillomavirus infection uncouples cell cycle checkpoints
via suppression of p53/pRB while retaining wild-type gene
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expression, overcome in the case of the dramatic DNA damage that
results from combination CRT (Kimple et al, 2013; Reickmann
et al, 2013). However, in head and neck cancers, improved survival
is also seen in patients with p16þ tumours treated with surgical
excision alone, suggesting that further inherent factors are involved
(Licitra et al, 2006). Relapse rates of around 25% in p16þ anal
cancers suggest that these patients can be further stratified to
identify those at ‘high risk’, with additional mechanisms and
biomarkers as yet undiscovered.
An alternative hypothesis is that viral antigens elicit a host
immune response directed against the tumour cells. Human
papillomavirus 16-E6 and -E7-specific T cells have been identified
in HPV-driven oropharyngeal cancer patients as part of an
adaptive immune response, and tumour-infiltrating lymphocytes
(TILs) are associated with improved outcomes in a number of
different tumour types (Mei et al, 2014; Matsumoto et al, 2015).
Specifically in the case of HPV-associated oropharyngeal cancer,
the degree of TILs can be used to stratify the HPVþ patients into
‘high-risk’ and ‘low-risk’ groups, where HPVþ tumours with only
low TIL scores have similar outcomes to the HPV tumours
(Ward et al, 2014). Patients with HPVþ /TIL high had a 3-year
overall survival of 96% vs 59% in the HPVþ /TIL low group.
The aim of this study was to investigate whether TILs play a similar
prognostic role in anal cancer, using two well-characterised cohorts
of tumours (i.e. known p16 status) treated with radical radiotherapy
þ / concurrent chemotherapy with curative intent and docu-
mented outcomes (Gilbert et al, 2013, Serup-Hansen et al, 2014).
MATERIALS AND METHODS
Collection of cohorts. This work has ethical approval
(11/LO/0323). Clinical details were retrieved for patients treated
with radical radiotherapy þ / concurrent chemotherapy with
curative intent for non-metastatic squamous cell carcinomas of the
anus and anal canal between 2004 and 2009 inclusive at the Sussex
Cancer Centre, Brighton, and the Kent Oncology Centre,
Maidstone, UK, as previously described (Gilbert et al, 2013). The
Danish cohort comprised patients presenting to the Department of
Oncology at Herlev Hospital (Herlev, Denmark) with newly
diagnosed AJCC stage I–III anal cancer, between January 2000 and
January 2010 (Serup-Hansen et al, 2014).
TIL scoring. Haematoxylin and eosin (H&E) stained slides were
obtained from a representative formalin-fixed paraffin-embedded
block from each tumour sample. Lymphocyte infiltrations were
scored by a pathologist blinded to patient demographics or
outcomes (GJT), using a low-power magnification ( 2.5 objec-
tive). As described previously (Ward et al, 2014), tumour TILs
were scored as high (3 – diffuse, present in480% tumour/stroma),
moderate (2 – patchy, present in 20–80% tumour/stroma) or low
(1 – weak/absent, present in o20% tumour/stroma).
Statistical analysis. Associations between TIL score and other
clinic-pathological characteristics were evaluated using Pearson’s
correlation coefficient. The primary end point was relapse-free
survival, defined as time from histological diagnosis of anal cancer
to date of diagnosis of confirmed relapse (local or distant as
recorded by the clinical team) or date of last follow-up, analysed
using Kaplan–Meier plots and log-rank tests using SPSS 22.0
(IBM, Armonk, NY, USA), tabulating RFRs.
RESULTS
UK cohort. In all 153 patients were available for analysis
(Table 1), with a median follow-up of 27.9 months. Of these,
97 were female and 56 male. Tumour-infiltrating lymphocyte
scores were available for 141 cases (representative images;
Figure 1); 12 cases were excluded where insufficient tumour
material was available. Of these, 126 were p16þ (Gilbert et al,
2013), with an RFR of 73.8% as opposed to 33.3% in the 15 p16
tumours. There was no correlation between TIL score and patients’
sex or p16 immunohistochemistry.
Table 1. UK and Danish anal cancer cohorts, demographics




Male (%) 56 (36.6) 33 (25.2)
Female (%) 97 (63.4) 98 (74.8)
Relapse (RFR%) 106 (69.3) 33 (74.8)
p16
p16þ (%) 137 (89.5) 121 (92.4)
p16 (%) 16 (10.5) 10 (7.6)
p16 and relapse
p16þ relapse (%RFR) 37/137 (73.0) 26/121 (78.5)
p16 relapse (%RFR) 10/16 (37.5) 7/10 (30)
TIL
TIL1 (%) 29 (18.9) 23 (17.6)
TIL2 (%) 85 (55.5) 73 (55.7)
TIL3 (%) 27 (17.6) 26 (19.8)
TIL not available (%) 12 (7.8) 9 (6.9)
TIL and relapse
TIL1 relapse (%RFR) 16/29 (44.8) 5/23 (78.3)
TIL2 relapse (%RFR) 23/85 (72.9) 25/73 (65.8)
TIL3 relapse (%RFR) 4/27 (85.2) 2/26 (92.3)
Whole cohort, p16
TIL1 relapse (%RFR) 4/6 (33.3)
TIL2 relapse (%RFR) 11/16 (31.3)
TIL3 relapse (%RFR) 2/3 (33.3)
Whole cohort, p16þ
TIL1 relapse (%RFR) 17/46 (63.0)
TIL2 relapse (%RFR) 37/142 (73.9)
TIL3 relapse (%RFR) 4/50 (92.0)
Abbreviations: p16¼ immunohistochemistry for p16INK4a; RFR¼ relapse-free rate; TIL¼






Figure 1. Representative anal cancer specimens stained with
haematoxylin and eosin demonstrating examples with (A), low/absent
and (B), high levels of tumour-infiltrating lymphocytes corresponding
to TIL1 and TIL3 respectively. Scale bar denotes 10 mm.
Tumour-infiltrating lymphocytes in anal cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.448 135
Tumour-infiltrating lymphocyte score was significantly asso-
ciated with relapse-free survival (Figure 2A, log-rank test
P¼ 0.004), where tumours with a TIL score 3 had an RFR of
85.2% as opposed to 72.9% for TIL2 and 44.8% for those with weak
or absent TILs.
Danish cohort. One hundred thirty-one patients were included in
the analysis, with a median follow-up of 51.2 months. Of these,
98 were female and 33 male (Table 1). As previously described
(Serup-Hansen et al, 2014), 121 (92.3%) were positive for p16
immunohistochemistry, with an RFR of 78.5%, as opposed to
30% in the 10 cases that were p16 . Tumour-infiltrating
lymphocyte scores were available for 122 cases; 9 cases were
excluded where insufficient tumour material was available. Again
there was no correlation between TIL score and sex or p16
immunohistochemistry.
Tumour-infiltrating lymphocyte score was again associated with
relapse-free survival (Figure 2B and log-rank test P¼ 0.033),
although here the biggest distinction was between TIL3 and TILs
1–2 (weak/absent to moderate). Patients with high TILs had a RFR
of 92.3%, as opposed to 65.8% with a moderate infiltrate of TILs
and 78.3% when TILs were absent or weakly infiltrating.
Combined analysis of cohorts with respect to p16 status. In
order to better understand the relative contribution of TIL scoring
in the context of p16 status in line with the HNSCC model
previously proposed (Ward et al, 2014), the two cohorts
were combined and survival analyses performed on the p16þ
and p16 populations (Table 1, Figure 2C and D). Tumour-
infiltrating lymphocyte scores did not add prognostic value to the
25 cases that were negative for p16 (log-rank test P¼ 0.416),
but effectively stratified the outcomes in the 263 patients with
p16þ tumours (log-rank test P¼ 0.006), with RFRs ranging
from 63% for the TIL1 cases to 92% in the TIL3 tumours.
In a multivariate analysis including sex, p16 and TIL score, TIL
retained independent prognostic value (P¼ 0.001).
DISCUSSION
A number of studies have shown that, in keeping with the situation
described in head and neck cancer, anal cancers associated with
HPV have better outcomes following CRT than those that are HPV
or p16 . Previous explanations for this have centred on
differential levels of p53 mutation, either directly measured
(Meulendijks et al, 2015) or implied through immunohistochem-
istry for p53 (Lampejo et al, 2010). However, an additional factor
might be variations in the adaptive immune response elicited by
virally driven tumours. As one component of this, TILs provide a
morphological correlate of the host immune response and, as we
have demonstrated, may give additional prognostic value over and
above assessment of the HPV status of tumours via HPV
genotyping or immunohistochemistry for p16. Prior data from
anal cancer are limited and inconsistent (Grabenbauer et al, 2006;
Rubio et al, 2008). Whether these differences are derived from
tumour- or host-related factors will be the subject of further
research. Given the high rates of HPV/p16 positivity of B90% in
contemporary anal cancer (Baricevic et al, 2015), the ability of TIL
to stratify outcomes in the p16þ population is arguably even more
relevant than in head and neck cancer.
Larger data sets are required to demonstrate the reproducibility
of TIL score and build a multivariate model incorporating TIL
scores with established prognostic factors (p16/HPV, stage, sex,
detailed smoking history) and correlate any prognostic effect on
overall survival (we used relapse-free survival as salvage surgery is
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Figure 2. Kaplan–Meier relapse-free survival curves and log rank test P values; (A) For UK cohort stratified by TIL 1–3; (B) for Danish cohort
stratified by TIL 1–3; (C) combined cohorts, p16– cases stratified by TIL 1–3; and (D) combined cohorts, p16þ cases stratified by TIL 1–3.
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validation in prospective studies. This work is underway and
should inform future trials exploring increased radiotherapy doses
or novel agents in poor-risk cases, or ‘de-escalation’ strategies in
good prognosis tumours where avoidance of late toxicity is
desirable. The marked biological and clinical relevance of the TIL
response demonstrated here supports trials of immunotherapy in
anal cancer, whether targeting immune checkpoints via anti-
CTLA4/PD1/PDL1 agents (including in the concurrent or (neo)
adjuvant setting; Illidge, 2015), or using adoptive T-cell therapy as
demonstrated in head and neck and cervical cancer (Hald et al,
1994; Stevanovic´ et al, 2015).
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